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Background: Parents are increasingly faced with decisions about optional newborn bloodspot screening (NBS) despite
no consistent policy for communicating information about such testing. We examined whether framing optional NBS
alongside mandatory NBS influenced intention to participate in optional NBS.
Methods: For this Internet-administered study, 2,991 adults read a hypothetical vignette in which optional NBS for
Duchenne muscular dystrophy (DMD) was either presented by itself (in isolation), alongside a description including
the total number of mandatory NBS tests (“bundled” mandatory context), or alongside a listing of each mandatory
NBS test (“unbundled” mandatory context). We assessed associations with participants’ intended participation using
ordered logistic regression models, and associations with attitudes towards optional DMD NBS and subjective
norms using Analysis of Variance.
Results: Participants were more likely to choose optional DMD NBS if they also read information about mandatory
NBS (either bundled or unbundled) versus when DMD NBS was presented in isolation. Participants who read about
optional DMD NBS in isolation also reported such testing to be less important and that they would worry more
about the results than those who also saw mandatory NBS information.
Conclusions: Future NBS programs should pay attention to the framing of optional testing communication, as it
influences parental behavior. Predictors of NBS uptake will become increasingly important as NBS programs
continue expanding.
Keywords: Newborn screening, Decision making, Duchenne muscular dystrophy, Optional newborn screeningBackground
Newborn bloodspot screening (NBS) is a highly success-
ful public health program aimed at the early identifica-
tion of babies with potentially devastating conditions
that benefit from pre-symptomatic diagnosis and treat-
ment. In the United States alone, over 4 million infants
per year are screened through state-based mandatory
programs [1]. The number of disorders included in NBS
programs has greatly increased over the last decade due
to advances in testing technology [2, 3]. During this
period the American College of Medical Genetics advo-
cated for a uniform core NBS panel of 29 conditions,
which most states adopted [4].
Since the release of the Recommended Uniform
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screened. However, states can still screen for conditions
beyond the Recommended Uniform Screening Panel
(e.g., New York State includes NBS for Krabbe Disease),
leading to variation in NBS programs [6]. Adding further
to this inconsistency is the existence of “pilot studies”,
which offer optional NBS for diseases not included in
mandatory NBS panels for which there is limited treat-
ment efficacy data [7, 8]. Such pilot studies evaluate the
efficacy and safety of adding a new test into mandatory
NBS programs [8]. In addition to this inconsistency in the
conditions NBS programs test for, there is inconsistency in
the timing, methods, and sources of information that
parents receive about NBS [9]. The expansion of NBS and
variability in how NBS information is delivered, including
what information is included and the way in which this
information is presented, leads to questions about how
optional NBS, increasingly available, is communicated.le distributed under the terms of the Creative Commons Attribution License
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. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Lillie et al. BMC Medical Informatics and Decision Making  (2015) 15:50 Page 2 of 7Thus far, most research on optional NBS has focused
on parental knowledge and attitudes, finding over-
whelming parental support for NBS [10–17]. Although
few studies have assessed attitudes towards information
provision, addressing the timing and source of informa-
tion [9, 18], no studies have explored the framing of
optional NBS, specifically the mandatory NBS context in
which optional NBS is presented. For example, several
pilot programs have offered optional NBS for Duchenne
muscular dystrophy (DMD), most recently the Centers
for Disease Control-funded Statewide Newborn Screen-
ing for Duchenne Muscular Dystrophy at the Columbus
Children’s Research Institute in Ohio [19]. DMD is a
rare, lethal form of muscular dystrophy that does not
fulfill the criteria for inclusion in mandatory NBS; there
is no effective treatment that justifies earlier testing in
the newborn period [20, 21]. Researchers have studied
DMD NBS attitudes and recently begun to identify
factors influencing the parental decision-making process
in DMD NBS [17, 22–24], but the context of how DMD
NBS information is presented has yet to be studied.
DMD NBS could be presented by itself, which may
encourage parents to consider it solely based on its in-
trinsic characteristics. Alternately, it could be presented
with information about existing mandatory NBS pro-
grams, either generalized information or detailed. It is
unclear whether framing optional NBS in this way would
encourage its use by connecting parents to the pros of
mandatory NBS, or discourage it by making optional
NBS seem trivial or excessive, as yet another test on top
of the many already being done.
To explore the question of whether contextual framing
of optional NBS affects decision making, we conducted
an experimental study in which we randomized whether
an optional NBS test (DMD NBS) was presented by
itself, in comparison with a description of mandatory
NBS that simply described the total number of tests,
or as part of a description of mandatory NBS that listed
each mandatory test separately. We assessed the effect
of these conditions on DMD NBS intention and
attitudes about DMD NBS.
Methods
Study population
We recruited adult Internet users through Amazon’s
Mechanical Turk (MTurk), an online marketplace for
people willing to complete tasks (such as surveys) that
cannot be automated [25]. Inclusion criteria included
age 21 years or older, United States resident, and the
ability to complete a web-based survey in English.
Because MTurk users tend to be younger adults, we
expected that this sampling strategy would yield
mostly adults who were either relatively recent parents or
potentially contemplating having children. Participantswere paid $0.75 upon completion of the survey, which is
consistent with prevailing rates on MTurk for surveys of
this length. This study was declared exempt by the Institu-
tional Review Board at the University of Michigan.
Procedure
To begin each study, participants read a vignette that
outlined a hypothetical situation in which they have a
newborn son and are presented with basic information
about optional DMD NBS. Participants then read a
brochure that provided a detailed description of DMD
and DMD NBS. Participants were randomized into one of
the three experimental groups: isolation context, bundled
mandatory NBS context, and unbundled mandatory NBS
context. For those in the isolation context group, the
brochure discussed only the optional NBS; mandatory
NBS was not mentioned. Participants in the bundled
mandatory NBS context group saw a brochure in which
mandatory NBS was discussed, but only as an aggregated
package (“50 tests”). Participants in the unbundled
mandatory NBS context group saw a more detailed
brochure in which each of the 50 mandatory NBS tests
was listed separately. The purpose of the bundled and
unbundled presentations was to frame DMD NBS in the
context of mandatory NBS, either as an addition to a
single package of tests (bundled) or as an addition to an
exhaustive list of tests (unbundled). See Additional file 1
for the exact brochures shown to participants. The format
of and basic information included in the brochures were
modeled after the study brochure from the Statewide
Newborn Screening for Duchenne Muscular Dystrophy at
the Columbus Children’s Research Institute [19].
Measures
The main outcome measure was intention to participate
in DMD NBS. After reading the vignette and brochure,
participants reported how likely it was that they would
choose DMD NBS (4-point Likert scale; “Very Unlikely”
to “Very Likely”). Due to the hypothetical nature of this
study, we wanted to identify those participants who had
a clear desire for NBS. Therefore for our analyses this
variable was dichotomized into chose DMD NBS (score
of 4) vs did not chose DMD NBS (score of 1–3).
Participants answered eight questions that assessed
their attitudes about DMD NBS, drawn from previous
qualitative work regarding parents’ responses to DMD
NBS [13, 14]. First, participants rated the importance
of…1) DMD NBS; 2) seeing the results of DMD NBS;
and 3) sharing the results of DMD NBS (5-point Likert
scales; “Not at all Important” to “Very Important”). Then
participants responded to the following five questions/
statements, each on a 5-point Likert scale: 1) How much
do you think you would worry about the results of your
baby’s DMD test? (“Not at all” to “Very Much”); 2) The
Table 1 Participant characteristics (N = 2,991)a
Characteristic % (N)
Age (range, mean SD) 21-82, 29.3 (9.5)
21-35 81.1 (2,099)
36 and older 18.9 (489)
Race
White 79.9 (2,387)








Not married/partnered 60.1 (1,791)
Education Level
Some high school 1.1 (34)
High school/GED 8.7 (259)
Some college/Tech 37.1 (1,109)
College degree 42.1 (1,259)
Advanced degree 11.0 (328)
Household Income
<$14.5kb 15.0 (448)
$14.5 to < $35 k 26.0 (776)
$35 k to < $50 k 19.3 (575)
$50 k to < $75 k 19.1 (570)
$75 k - < $100 k 11.1 (330)




Don’t Know 1.0 (30)
aN varies due to missing data. Percentage missing data < 0.50 % for all
variables except age (13.41 % missing)
bk = thousand
cOwn or partner’s pregnancy
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for the future (“Strongly Disagree” to “Strongly Agree”);
3) The information from the DMD test would affect
whether I have more children (“Strongly Disagree” to
“Strongly Agree”); 4) The results from the DMD test
may affect how I treat my child (“Strongly Disagree” to
“Strongly Agree”); 5) My child would be treated differ-
ently by others if he is diagnosed with DMD (“Strongly
Disagree” to “Strongly Agree”).
Of course, decision making also occurs within a social
context [26], and subjective norms have influenced both
newborn [27] and prenatal [28] screening. Thus we
assessed the influence of optional NBS framing on social
normative beliefs around two topics: NBS in general and
DMD NBS specifically. Participants answered two ques-
tions (7-point Likert scale; “Agree” to “Disagree”): 1) Do you
think that most people agree or disagree that it is import-
ant for babies to be tested for as many genetic diseases as
possible?; and 2) Do you think that most people agree or
disagree with getting DMD NBS?. We expected that pre-
senting DMD NBS within the context of the larger,
mandatory NBS program would lead to stronger subject-
ive norm attitudes.
At the end of the survey, participants reported demo-
graphic information, including age, race, gender, marital/
partnered status, level of education, and household income.
We assessed participants’ experiential knowledge of NBS,
measured by either their or a partner’s pregnancy history.
Analysis plan
To examine the influence of contextual framing on
choosing optional DMD NBS, we conducted ordered lo-
gistic regression analyses (with and without demographic
predictors) using the dichotomized intended participa-
tion variable. We also conducted ANOVA analyses to
test the influence of contextual framing on attitudes
about DMD NBS. Control factors included demographic
variables and previous pregnancy. All analyses were
completed using STATA [Stata Statistical Software: Re-
lease 12. College Station, TX: StataCorp LP].
Results
Study participants
A total of 3,215 participants completed surveys; 224 sur-
veys were excluded for participants reporting an age less
than 21 years per the exclusion criteria, resulting in a
final N of 2,991. Participants were predominately white
(79.9 %), male (52.4 %), and had no history of pregnancy
(63.0 %). The minority (39.9 %) were married/partnered.
The average age was 29.3 years (range 21–82, SD = 9.5;
81.1 % under 36 years). A large minority of participants
(42.1 %) had a college degree, but 9.8 % had a high
school education or less. See Table 1 for full participant
characteristics.Influence of contextual framing on intended participation
in DMD NBS
Participants given information about DMD NBS in a
mandatory NBS context (either bundled or unbundled)
were more likely to choose DMD NBS, compared to
those given information without any reference to
mandatory NBS (Bundled: OR = 1.43, CI=1.16, 1.75,
p < 0.01; Unbundled: OR = 1.38, CI=1.13, 1.68, p < 0.01).
Certain demographic characteristics predicted likelihood
of choosing DMD NBS (Table 2). In particular, previous
Table 2 Predictors of choosing Duchenne muscular dystrophy
(DMD) newborn screening (NBS) (N = 2,562)a
Variable OR (95 % CI)
Contextual Framing
Isolation Reference
Bundled mandatory NBS 1.43 (1.16, 1.75)**
Unbundled mandatory NBS 1.38 (1.13, 1.68)**
Age
21-35 Reference
36 and older 0.95 (0.75, 1.19)
Race
White Reference
African American 0.64 (0.45, 0.90)*
Asian 1.36 (0.98, 1.89)
Other 1.11 (0.79, 1.58)
Gender
Male Reference
Female 1.19 (1.00, 1.41)
Marital Status
Married/partnered Reference
unmarried/partnered 1.12 (0.91, 1.37)
Education Level
College/Adv degree Reference
Some college/Tech 1.13 (0.94, 1.35)
High school or less 0.74 (0.56, 0.98)*
Income
<$35 k Reference
$35 k to < $75 k 1.16 (0.95, 1.40)
$75 k and over 1.14 (0.90, 1.44)
Previous Pregnancy
No Reference
Yes 0.65 (0.53, 0.80)***
*p < 0.05, **p < 0.01, ***p < 0.001
aDichotomized variable (4 vs. 1–3)
Lillie et al. BMC Medical Informatics and Decision Making  (2015) 15:50 Page 4 of 7pregnancy, lower education attainment, and African
American race all predicted lower intention to pursue
optional DMD NBS.
Influence of contextual framing on attitudes about DMD
NBS
As shown in Table 3, there were framing effects on
DMD NBS attitudes. Participants who read about DMD
NBS without the context of mandatory NBS (isolation
group) reported DMD NBS to be less important and
reported that they would worry more about DMD NBS
results than those who saw either a bundled or unbundled
panel (F = 3.40, p < 0.05; F = 3.48, p < 0.05, respectively).Participants’ social normative beliefs (i.e., reporting how
they think what most other people believe) were asso-
ciated with bundling; those who viewed DMD NBS
without the context of mandatory NBS reported signi-
ficantly weaker social normative beliefs around the
endorsement of both NBS in general and DMD NBS
specifically than those who also viewed mandatory NBS
(in either the bundled or unbundled format) (F = 20.01,
p < 0.01; F = 9.29, p < 0.01, respectively).
Discussion
Parents are increasingly faced with the decision whether
or not to participate in optional NBS as technology
advances. Questions about how best to present such
testing will become more important as NBS programs
expand. This is the first study to look at the influence of
contextual framing of optional NBS information on
intended participation. Our results suggest that when
people were not given the context of broader mandatory
NBS, they were more hesitant to choose optional NBS
testing and found it less appealing overall.
Recent work has identified factors of information
presentation and choice that influence NBS decision
making, including the routinization of procedure [22]
and distinct optional NBS invitations [24]. Our study
suggests that framing within NBS programs is another
influence. It is possible that reading about mandatory
NBS as a context for DMD NBS reminded partici-
pants about the benefits of NBS. Those participants
were primed to consider the value of optional DMD
NBS and evaluated the benefits of optional NBS dif-
ferently. It is also possible that after viewing the
number of mandatory NBS tests (either as “50” or by
test), participants saw DMD NBS as just another test
to add to the list.
Participants reading about DMD NBS in the context
of mandatory NBS (either bundled or unbundled) re-
ported the test to be more important and that they
would worry less about the results. This is consistent
with previous research finding parents without general
NBS information had higher levels of worry after their
infants' abnormal cystic fibrosis NBS, compared to
parents with basic NBS information [29]. They also
had stronger subjective normative beliefs around the
endorsement of both NBS in general and the optional
NBS test specifically, which have previously been
shown to influence actual NBS decisions [27]. Taken
together, our results suggest that the existence of
accompanying mandatory NBS information, whether
bundled or not, seemed to be very relevant to partici-
pants’ interest in optional NBS tests. Additionally, our
patient characteristic findings that having a previous
pregnancy and identifying as African American made one
less likely to choose DMD NBS mirrors previous research,
Table 3 Attitudes about Duchenne muscular dystrophy (DMD) newborn screening (NBS)
Mandatory NBS Context
Attitude Measure Bundled Unbundled No Context
Mean (SD) Mean (SD) Mean (SD) F
Subjective norms around NBS in generala 5.64 (1.52) 5.71 (1.49) 5.30 (1.63) 20.01**
Subjective norms around DMD NBSa 5.53 (1.57) 5.60 (1.54) 5.31 (1.56) 9.29**
How important is it to test for DMD?b 4.08 (1.09) 4.12 (1.00) 4.00 (1.05) 3.40*
How important is it to see the results?b 4.42 (0.98) 4.46 (0.90) 4.38 (1.01) 1.80
How important is it to share the results?b 2.68 (1.34) 2.62 (1.31) 2.61 (1.35) 0.74
How much would you worry about resultsc 3.42 (1.25) 3.45 (1.20) 3.56 (1.20) 3.48*
Results may help me prepare for the futured 4.39 (0.83) 4.41 (0.79) 4.39 (0.77) 0.21
Results may affect if I have more childrend 3.21 (1.22) 3.19 (1.19) 3.20 (1.21) 0.08
Results may affect how I treat my childd 2.89 (1.35) 2.93 (1.34) 2.92 (1.35) 0.24
Others would treat my child differentlyd 3.58 (1.06) 3.64 (0.96) 3.66 (1.02) 1.73
*p < 0.05, **p < 0.01
a7-point Likert scale: 1 = Most people agree that it is important for babies to be tested for as many genetic diseases as possible/with getting the DMD test?;
7 = Most people disagree that it is important for babies to be tested for as many genetic diseases as possible/with getting the DMD test?
b5-point Likert scale: 1 = Not at all important; 5 = Very important
c5-point Likert scale: 1 = Not at all; 5 = Very much
d5-point Likert scale: 1 = Strongly disagree; 5 = Strongly agree
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in NBS decision making [17, 23] and African American
race in optional NBS [30].
Our findings are tempered by a few limitations. First,
our use of Internet-administered studies using hypothet-
ical scenarios may not have evoked the same feelings or
decision-making processes that would be present in a
true population of DMD NBS decision makers, actual
parents. However, our study materials mirrored those
used in real-world contexts, especially materials used at
the Columbus Children’s Research Institute for the
Statewide Newborn Screening for Duchenne Muscular
Dystrophy [19]. Second, our subject pool was also com-
prised of people who voluntarily chose to take surveys,
which may limit generalizability. Finally, by virtue of the
study design and study population, DMD NBS decision-
making was conceptualized as a solo process and not
one done with clinicians, partners and/or family mem-
bers. An ideal scenario is a well-informed decision that
includes at least two people [31]; in such a case the pres-
ence of additional decision makers may alter the impact
of how DMD NBS information is communicated. How-
ever, as previous research has shown, NBS decisions are
rarely an ideal process, with inconsistent information
and incomplete discussions [9, 32]. This is particularly
true for pilot NBS studies [33]. Thus, our study may ac-
tually resemble a true optional NBS decision: one made
quickly with little advance discussion or education.
Technological innovation has created a “therapeutic
gap”, in which one can screen for a disease before an ef-
fective treatment exists. With increasing advocacy [34]
and technology, the NBS therapeutic gap is likely tocontinue expanding. Therefore it is important to con-
sider the possible influences on decision makers before
policies and universal guidelines are set regarding the
communication of optional NBS information. Our find-
ings demonstrate the possibility of greater or lesser test
uptake simply due to structural differences in communi-
cations and program design, optional NBS managed as a
separate entity or as an add-on to either a single, bun-
dled package of mandatory NBS or as a panel of separate
mandatory NBS tests. This is an important finding for
clinicians to take note of; the context in which NBS tests
are presented has the power to affect parental attitudes
and decisions.
Conclusions
With clinical trials testing emerging DMD treatments
[35, 36], DMD NBS has come to the forefront of discus-
sions about the inclusion of optional NBS in mandatory
NBS [8, 37]. Our results suggest that viewing optional
NBS information without the larger context of mandatory
NBS impacts decision making. Several studies have
explored the challenges in NBS education [9, 38–40].
However, evidence-based studies with parents considering
optional NBS are needed to determine the relative import-
ance of various communication factors in driving parents’
decisions. The effect of context seemed important regard-
less of how much detail is provided regarding mandatory
NBS. Further research to improve our understanding of
the significant influences on parental decisions regarding
optional NBS decision making is required to inform future
optional NBS practices and to help guide clinical and
health communication practice as well as health policy.
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